The ?-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) favorably impact mitochondrial dysfunction and chronic inflammation in heart failure (HF). Treatment with DHA+EPA alters cardiac phospholipid composition by decreasing arachidonic acid (a pro-inflammatory fatty acid) and increasing DHA and the mitochondrial phospholipid cardiolipin, with is associated with improved LV function. Evidence for clinical effectiveness of DHA+EPA in HF patients comes from the GISSI-HF trial, in which a low dose of DHA+EPA (0.85g/day) modestly but significantly reduced mortality and hospitalization in HF patients. Our data suggest that a much higher dose (~3g/d) maybe ideal in HF patients, as is currently recommended for treatment of hypertriglyceridemia (3.4 g/day). Fish oil supplements contain a mix of DHA and EPA, however we postulate that DHA is superior to EPA in improving mitochondrial function and suppressing inflammation, and thus DHA should be used to treat HF. We found that DHA is more readily incorporated into tissue phospholipids than EPA, particularly in cardiac mitochondrial phospholipids like CL. Furthermore, DHA should be superior at decreasing arachidonic acid and inflammation. Thus our goal in Stage 1 is to determine if DHA is superior to EPA or DHA+EPA in increasing CL, improving mitochondrial function, decreasing arachidonic acid, suppressing inflammation, and prevent progression of HF Studies to evaluate this hypothesis will be performed in well established animal models of HF and in patients. Stage 1 has Specific Aims: 1) Determine if DHA is superior to EPA or DHA+EPA in its effects on LV remodeling in a large animal model of systolic HF. 2) Determine if DHA has a more beneficial impact than EPA or DHA-FEPA on survival, mitochondrial dysfunction, and LV remodeling in rodents with HF. 3) Conduct studies in humans to determine if DHA results in more favorable alterations in cardiac phospholipids than does DHA+EPA. 4) Prepare protocol and consortiums for the Stage 2 clinical study.

Public Health Relevance

Despite aggressive treatment, patients with heart failure have a poor prognosis. Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acids found in fish oils, may prevent the progressions of heart failure through mechanisms that are not addressed with current drugs. The goal of this grant is to determine if treatment with DHA will improve clinical outcomes in patients with heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory Grants (P20)
Project #
5P20HL101434-02
Application #
8053762
Study Section
Special Emphasis Panel (ZHL1-CSR-Y (F1))
Program Officer
Liang, Isabella Y
Project Start
2010-04-01
Project End
2012-03-31
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
2
Fiscal Year
2011
Total Cost
$660,348
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Ribeiro Jr, Rogerio F; Dabkowski, Erinne R; O'Connell, Kelly A et al. (2014) Effect of a high-protein diet on development of heart failure in response to pressure overload. Appl Physiol Nutr Metab 39:238-47
Galvao, Tatiana F; Khairallah, Ramzi J; Dabkowski, Erinne R et al. (2013) Marine n3 polyunsaturated fatty acids enhance resistance to mitochondrial permeability transition in heart failure but do not improve survival. Am J Physiol Heart Circ Physiol 304:H12-21
O'Connell, Kelly A; Dabkowski, Erinne R; de Fatima Galvao, Tatiana et al. (2013) Dietary saturated fat and docosahexaenoic acid differentially effect cardiac mitochondrial phospholipid fatty acyl composition and Ca(2+) uptake, without altering permeability transition or left ventricular function. Physiol Rep 1:e00009
Dabkowski, Erinne R; O'Connell, Kelly A; Xu, Wenhong et al. (2013) Docosahexaenoic acid supplementation alters key properties of cardiac mitochondria and modestly attenuates development of left ventricular dysfunction in pressure overload-induced heart failure. Cardiovasc Drugs Ther 27:499-510
Khairallah, Ramzi J; Kim, Junhwan; O'Shea, Karen M et al. (2012) Improved mitochondrial function with diet-induced increase in either docosahexaenoic acid or arachidonic acid in membrane phospholipids. PLoS One 7:e34402
Hecker, Peter A; Galvao, Tatiana F; O'Shea, Karen M et al. (2012) High-sugar intake does not exacerbate metabolic abnormalities or cardiac dysfunction in genetic cardiomyopathy. Nutrition 28:520-6
Galvao, Tatiana F; Brown, Bethany H; Hecker, Peter A et al. (2012) High intake of saturated fat, but not polyunsaturated fat, improves survival in heart failure despite persistent mitochondrial defects. Cardiovasc Res 93:24-32
Stanley, William C; Dabkowski, Erinne R; Ribeiro Jr, Rogerio F et al. (2012) Dietary fat and heart failure: moving from lipotoxicity to lipoprotection. Circ Res 110:764-76
Stanley, William C; Khairallah, Ramzi J; Dabkowski, Erinne R (2012) Update on lipids and mitochondrial function: impact of dietary n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 15:122-6
Khairallah, Ramzi J; O'Shea, Karen M; Brown, Bethany H et al. (2010) Treatment with docosahexaenoic acid, but not eicosapentaenoic acid, delays Ca2+-induced mitochondria permeability transition in normal and hypertrophied myocardium. J Pharmacol Exp Ther 335:155-62

Showing the most recent 10 out of 13 publications